间变性淋巴瘤激酶（ALK）阳性非小细胞肺癌食管转移所致食管狭窄在接受劳拉替尼治疗数天后缓解，未置入支架。 - Suppr

Esophageal Stricture Caused by ALK-Positive NSCLC Esophageal Metastasis Resolved After a Few Days of Lorlatinib Therapy Without Stent Placement.

作者信息

Longo Vito, Catino Annamaria, Montrone Michele, Pizzutilo Pamela, Ugenti Ippazio, Lacalamita Rosanna, Del Bene Gabriella, Pesola Francesco, Marech Ilaria, Galetta Domenico

机构信息

Medical Thoracic Oncology Unit, IRCCS Istituto Tumori "Giovanni Paolo II," Bari, Italy.

Digestive Endoscopy Unit, IRCCS Istituto Tumori "Giovanni Paolo II," Bari, Italy.

出版信息

JTO Clin Res Rep. 2020 Apr 18;1(2):100044. doi: 10.1016/j.jtocrr.2020.100044. eCollection 2020 Jun.

DOI:10.1016/j.jtocrr.2020.100044

PMID:34589934

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8474242/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/423b/8474242/8dd58263be1d/gr1.jpg

相似文献

Esophageal Stricture Caused by ALK-Positive NSCLC Esophageal Metastasis Resolved After a Few Days of Lorlatinib Therapy Without Stent Placement.间变性淋巴瘤激酶（ALK）阳性非小细胞肺癌食管转移所致食管狭窄在接受劳拉替尼治疗数天后缓解，未置入支架。

JTO Clin Res Rep. 2020 Apr 18;1(2):100044. doi: 10.1016/j.jtocrr.2020.100044. eCollection 2020 Jun.

Spotlight on lorlatinib and its potential in the treatment of NSCLC: the evidence to date.聚焦劳拉替尼及其在非小细胞肺癌治疗中的潜力：迄今的证据

Onco Targets Ther. 2018 Aug 22;11:5093-5101. doi: 10.2147/OTT.S165511. eCollection 2018.

Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.劳拉替尼用于治疗具有ALK或ROS1重排的非小细胞肺癌：一项国际多中心、开放标签、单臂首次人体1期试验。

Lancet Oncol. 2017 Dec;18(12):1590-1599. doi: 10.1016/S1470-2045(17)30680-0. Epub 2017 Oct 23.

Lorlatinib for the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer.洛拉替尼治疗间变性淋巴瘤激酶阳性非小细胞肺癌。

Expert Rev Clin Pharmacol. 2019 Mar;12(3):173-178. doi: 10.1080/17512433.2019.1570846. Epub 2019 Jan 30.

GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients.GLASS：ALK(+)和 ROS1(+)阳性 NSCLC 患者全球洛拉替尼回顾性研究：真实世界 123 例患者数据。

Lung Cancer. 2020 Oct;148:48-54. doi: 10.1016/j.lungcan.2020.07.022. Epub 2020 Jul 27.

Later-Line Treatment with Lorlatinib in - and -Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis.洛拉替尼用于ALK重排阳性非小细胞肺癌的后线治疗：一项回顾性多中心分析

Pharmaceuticals (Basel). 2020 Nov 7;13(11):371. doi: 10.3390/ph13110371.

Successful Treatment with Lorlatinib after the Development of Alectinib-Induced Liver Damage in ALK-Positive Non-Small-Cell Lung Cancer: A Case Report.阿来替尼诱导的肝损伤发生后，洛拉替尼成功治疗ALK阳性非小细胞肺癌：一例报告

Case Rep Oncol. 2021 Mar 1;14(1):197-201. doi: 10.1159/000513624. eCollection 2021 Jan-Apr.

Symptomatic CNS Radiation Necrosis Requiring Neurosurgical Resection During Treatment with Lorlatinib in -Rearranged NSCLC: A Report of Two Cases.在接受劳拉替尼治疗的间变性淋巴瘤激酶重排非小细胞肺癌中出现需要神经外科切除的症状性中枢神经系统放射性坏死：两例报告

Lung Cancer (Auckl). 2020 Jan 14;11:13-18. doi: 10.2147/LCTT.S224991. eCollection 2020.

Effect of polyglycolic acid sheet plus esophageal stent placement in preventing esophageal stricture after endoscopic submucosal dissection in patients with early-stage esophageal cancer: A randomized, controlled trial.聚乙二醇酸片加食管支架置入预防早期食管癌内镜黏膜下剥离术后食管狭窄的效果：一项随机对照试验。

World J Gastroenterol. 2018 Mar 7;24(9):1046-1055. doi: 10.3748/wjg.v24.i9.1046.

An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor-Refractory ALK-Positive or ROS1-Positive NSCLC.在接受过酪氨酸激酶抑制剂（TKI）治疗后进展的 ALK 阳性或 ROS1 阳性 NSCLC 患者中，通过早期或扩展准入计划评估劳拉替尼的疗效和安全性的国际真实世界分析。

J Thorac Oncol. 2020 Sep;15(9):1484-1496. doi: 10.1016/j.jtho.2020.04.019. Epub 2020 Apr 28.

引用本文的文献

Enteral lorlatinib after immune hyperprogression as a treatment option for anaplastic lymphoma kinase‑positive non‑small cell lung cancer: A case report.免疫超进展后使用肠内劳拉替尼治疗间变性淋巴瘤激酶阳性非小细胞肺癌：一例报告

Oncol Lett. 2023 Oct 23;26(6):526. doi: 10.3892/ol.2023.14113. eCollection 2023 Dec.

本文引用的文献

Drug resistance mechanisms in Japanese anaplastic lymphoma kinase-positive non-small cell lung cancer and the clinical responses based on the resistant mechanisms.日本间变性淋巴瘤激酶阳性非小细胞肺癌的耐药机制及基于耐药机制的临床反应。

Cancer Sci. 2020 Mar;111(3):932-939. doi: 10.1111/cas.14314. Epub 2020 Feb 8.

Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.洛拉替尼治疗 ALK 阳性非小细胞肺癌患者的疗效：一项全球性 2 期研究结果。

Lancet Oncol. 2018 Dec;19(12):1654-1667. doi: 10.1016/S1470-2045(18)30649-1. Epub 2018 Nov 6.

Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors.克唑替尼耐药的 NPM-ALK 突变体能使患者对不同的 Alk 抑制剂产生不同的敏感性。

Mol Cancer Res. 2013 Feb;11(2):122-32. doi: 10.1158/1541-7786.MCR-12-0569. Epub 2012 Dec 13.

Direct esophageal metastasis from a distant primary tumor is a submucosal process: a review of six cases.远处原发性肿瘤的食管直接转移是一种黏膜下病变：6例病例回顾

Dis Esophagus. 2001;14(3-4):247-50. doi: 10.1046/j.1442-2050.2001.00195.x.

Esophagectomy for metastatic carcinoma of the esophagus from lung cancer.用于治疗肺癌转移至食管的转移性食管癌的食管切除术。

Cancer. 1993 May 15;71(10):2958-61. doi: 10.1002/1097-0142(19930515)71:10<2958::aid-cncr2820711012>3.0.co;2-1.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Esophageal Stricture Caused by ALK-Positive NSCLC Esophageal Metastasis Resolved After a Few Days of Lorlatinib Therapy Without Stent Placement.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献